A rising single dose, randomized, placebo-controlled study to assess tolerability, safety, and pharmacokinetic of intravenous Tildrakizumab in healthy volunteers
Latest Information Update: 30 Nov 2018
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Spondylarthritis
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 30 Nov 2018 New trial record